Latest Breaking News On - Gerhard ehninger - Page 2 : comparemela.com
Share this article
DRESDEN, Germany, March 2, 2021 /PRNewswire/
GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced the publication of clinical data obtained from the ongoing Phase I study of their rapidly switchable UniCAR platform lead asset, UniCAR-T-CD123, in relapsed/refractory acute myeloid leukemia (rrAML), in the journal Blood .
The interim data of UniCAR-T-CD123 in rrAML, published online ahead of print as a letter in
Blood (Wermke et al. 2021, https://doi.org/10.1182/blood.2020009759), demonstrate that UniCAR-T-CD123 in rrAML is well-tolerated with rapid recovery of hematopoiesis and encouraging early efficacy. The Blood publication nicely underpins the clinical advantages of our rapidly switchable UniCAR platform, which have also been recently presented at the 3
Germany
German
Prnewswire-gemoa
Jana-fiebiger
Michael-pehl
Bristol-myers-squibb
Gerhard-ehninger
German-federal-ministry-for-education
Cell-meeting
Chief-medical-officer
Acute-leukemia
German-federal-ministry
Share this article
DRESDEN, Germany, Feb. 3, 2021 /PRNewswire/
GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced interim data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the Virtual 3
rd EHA-EBMT European CAR-T-Cell Meeting, which is held from February 04-06, 2021. The data are being presented as oral presentation by Dr. Martin Wermke, University Hospital Dresden, Germany (February 05, 12:20 CET) and as a poster presentation by Dr. Sabrina Kraus, University Hospital Würzburg, Germany (Abstract 68). These clinical results present a promising step forward as we continue to evaluate the safety and efficacy of UniCAR-T-CD123, said Professor Gerhard Ehninger, Chief Medical Officer of GEMoaB. We are highly encouraged by the fact that UniCAR-T-CD123 has demonstrated a favorable safety and efficacy profile in rrAM
Germany
German
Prnewswire-gemoa
Martin-wermke
Sabrina-kraus
Jana-fiebiger
Michael-pehl
Bristol-myers-squibb
Gerhard-ehninger
University-hospital
German-federal-ministry-for-education
University-hospital-dresden
vimarsana © 2020. All Rights Reserved.